Ascelia has just concluded a call providing a commercial road-map following the positive SPARKLE res...
EBIT -16% vs cons (SEK 50m vs 60m) and order intake -4% vs cons 80% of order book expected to be del...
Redeye comments on Invisio’s Q1-results which were in line with our expectations and the company saw...
Significant Q1 EBITA beat and comps are getting easier from Q2 Intensified key partnerships and supp...
Redeye will likely keep its forecasts and Base Case largely unchanged following a stable Q1 report m...
Redeye comments on Ultimovacs’ Q1 2024 report, following its INITIUM top-line failure and announced ...
Suominen’s Q1 earnings gained y/y, however the improvement pace was slower than we estimated as EBIT...
Aspo’s Q1 results were burdened by political strikes in Finland especially in the case of ESL, which...
Q1 EBITDA of 13.0m, below ABGSCe USD 15m on higher costs No changes to guidance - Strategic review s...
Redeye saw sales that were just above and results that were below our expectations.
Redeye comments on GiG’s Q1-results which were softer than expected, owing to somewhat lower-than-ex...
Q1 adj. EBITDA 18% below cons, primarily on Platform & Sportsbook Solid start to Q2 with Media sales...
Redeye concludes that Railcare had a solid start to the year.
Redeye considers Arise’s Q1 2024 report to be better than expected, as the production segment manage...
Redeye provides its initial comments on the Q1 2024 report from Scandinavian Chemotech, which was br...
Redeye saw a report where the first sales were reported for Terclara, and the cost aligned with expe...
Redeye notes that Q1 sales were slightly lower than our estimates; however, EBIT aligned with our fo...
Flattish sales on tough comps, EBITA +31% vs cons on higher GM Stabilised market with improvements i...
Redeye comments on I-Tech’s Q1 figures beating our expectations across the board.
43% beat on EBIT Expected launch of new product delayed EBIT '24e expected to be revised up 7-10% Q...
